Skip to main content

Revisions of Antimigraine Agents (Triptans) Prior Authorization Clinical Criteria Scheduled for April 4, 2023

Last updated on 3/3/2023

This article has been updated. For the updated information, click here.

On April 4, 2023, the Texas Health and Human Services Commission (HHSC) will revise the prior authorization clinical criteria for antimigraine agents (triptans).

This revision will add a step to check for the maximum dose per 30 days of therapy as stated in the products' package inserts for established drug safety dosing. The modifications to the criteria include the following:



Therapy Duration


Above 20 mg

Per 30 days


Above 100 mg

Per 30 days


Above 22.5 mg

Per 30 days


Above 120 mg

Per 30 days


Above 32 mg

Per 30 days


Above 240 mg

Per 30 days


900 mg

Per 30 days


40 mg

Per 30 days

The antimigraine agents (triptans) prior authorization clinical criteria guide is optional for managed care organizations (MCOs).

The Pharmacy Clinical Prior Authorization Assistance Chart shows each MCO's prior authorizations and how these authorizations relate to those used for processing fee-for-service Medicaid claims. This chart is updated quarterly.

Providers can also refer to the MCO Resources for links to each MCO's list of clinical prior authorizations.

Email with comments or questions.